Top CDMO in APAC
Nominate a Company
Usually, the qualified subscribers of our magazine nominate companies with whom they have collaborated and experienced exceptional results to be in this list. Did a company you recently worked with give you stellar results and ROI? Did it turn out to be one you would wholeheartedly recommend to peers? Or do you know of such an outstanding company through your network? Please fill in the details below and nominate them to be featured here.
Top CDMO in APAC
CDMO News
Lentiviral Vector Design for Clinical Readiness
Friday, October 09, 2026
Lentiviral vector programs often incur their most expensive delays long before a GMP batch is scheduled. A construct that performs at research scale may still require redesign once manufacturability or scale behavior becomes visible. By then, assay work and regulatory planning may already depend on the original design. The stronger manufacturing partner tests those decisions early, treating vector architecture as part of the path to GMP rather than a handoff to be solved later. Executives should look closely at how quickly a provider can establish that a construct is suitable for production and whether scale-up assumptions are built into development from the outset. Technical depth is bet
Selecting an Integrated Biologics CDMO for Development Continuity
Tuesday, September 22, 2026
Biologics programs can lose time at the handoffs between early development and manufacturing. A cell line may be technically sound yet create downstream purification burdens, while formulation choices made too late can complicate scale-up, stability work, technology transfer and filing preparation. For executives choosing an integrated biologics CDMO, the central question is not how many services sit on one menu. It is whether decisions made at one stage remain visible to the teams responsible for the next stage. That distinction becomes visible in project governance. Sponsors need enough transparency to understand schedule movement before a missed milestone becomes a broader pr
Integrated Biologics CDMOs: Building End-to-End Manufacturing Strength across APAC
Friday, September 18, 2026
Integrated biologics CDMOs are becoming important partners across the Asia-Pacific (APAC) life sciences sector as drug developers seek faster, more coordinated routes from early development to commercial manufacturing. These providers combine cell line development, process design, analytical services, clinical production, fill-finish support and large-scale manufacturing within connected operating models. The value lies in reducing handoffs between vendors while improving technical continuity, program visibility and manufacturing readiness. For biotechnology and pharmaceutical companies, integrated CDMO relationships can support speed, cost control and risk management. Strong pr
